Circulating Liver-enriched Antimicrobial Peptide-2 Decreases During Male Puberty

dc.contributor.authorVarimo Tero
dc.contributor.authorMiettinen Päivi J
dc.contributor.authorVaaralahti Kirsi
dc.contributor.authorToppari Jorma
dc.contributor.authorHuopio Hanna
dc.contributor.authorVoutilainen Raimo
dc.contributor.authorTenhola Sirpa
dc.contributor.authorHero Matti
dc.contributor.authorRaivio Taneli
dc.contributor.organizationfi=InFLAMES Lippulaiva|en=InFLAMES Flagship|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=lastentautioppi|en=Paediatrics and Adolescent Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organizationfi=väestötutkimuskeskus|en=Centre for Population Health Research (POP Centre)|
dc.contributor.organization-code1.2.246.10.2458963.20.42471027641
dc.contributor.organization-code1.2.246.10.2458963.20.68445910604
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id174920334
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/174920334
dc.date.accessioned2022-10-27T12:15:55Z
dc.date.available2022-10-27T12:15:55Z
dc.description.abstract<p><strong>Context: </strong>Circulating levels of liver-enriched antimicrobial peptide 2 (LEAP2), a ghrelin receptor antagonist, decrease under caloric restriction and increase in obesity. The role of LEAP2 in male puberty, a phase with accelerated energy demand, is unclear.</p><p><strong>Objective: </strong>This work aimed to investigate whether circulating LEAP2 levels are downregulated in boys following the onset of puberty to respond to the energy need required for growth.</p><p><strong>Methods: </strong>We determined circulating LEAP2 levels in 28 boys with constitutional delay of growth and puberty (CDGP) who participated in a randomized controlled trial (<a href="http://clinicaltrials.gov/show/NCT01797718" title="See in ClinicalTrials.gov">NCT01797718</a>), and were treated with letrozole (n = 15) or intramuscular low-dose testosterone (T) (n = 13) for 6 months. Blood sampling and dual-energy x-ray absorptiometry-measured body composition were performed at 0-, 6-, and 12-month visits.</p><p><strong>Results: </strong>Serum LEAP2 levels decreased statistically significantly during pubertal progression (0-6 months: mean decrease -4.3 [10.3] ng/mL, <em>P</em> = .036 and 0-12 months: -3.9 [9.3] ng/mL, <em>P</em> = .033). Between 0 and 6 months, the changes in serum LEAP2 levels correlated positively with changes in percentage of body fat (<em>r</em> <sub>s</sub> = 0.48, <em>P</em> = .011), and negatively with growth velocity and estradiol levels (<em>r</em> <sub>s</sub> = -0.43, <em>P</em> = .022, <em>r</em> <sub>s</sub> = -0.55, <em>P</em> = .003, respectively). In the T group only, the changes in serum LEAP2 correlated negatively with changes in T and estradiol levels. Between 0 and 12 months, the change in LEAP2 levels correlated negatively with the change in high-density lipoprotein levels (<em>r</em> <sub>s</sub> = -0.44, <em>P</em> = .022) and positively with the change in insulin (<em>r</em> <sub>s</sub> = 0.50, <em>P</em> = .009) and HOMA-IR (r<sub>s</sub> = 0.51, <em>P</em> = .007) levels.</p><p><strong>Conclusion: </strong>Circulating LEAP2 levels decreased after induction of puberty reciprocally with increased growth rate and energy demand, reflecting the metabolic state of the adolescent. Further, the results suggest that estradiol levels may have a permissive role in downregulating circulating LEAP2 levels.</p>
dc.identifier.olddbid174309
dc.identifier.oldhandle10024/157403
dc.identifier.urihttps://www.utupub.fi/handle/11111/34114
dc.identifier.urlhttps://doi.org/10.1210/jendso/bvac013
dc.identifier.urnURN:NBN:fi-fe2022081153831
dc.language.isoen
dc.okm.affiliatedauthorToppari, Jorma
dc.okm.affiliatedauthorDataimport, Lastentautioppi
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherENDOCRINE SOC
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1210/jendso/bvac013
dc.relation.ispartofjournalJournal of the Endocrine Society
dc.relation.issue3
dc.relation.volume6
dc.source.identifierhttps://www.utupub.fi/handle/10024/157403
dc.titleCirculating Liver-enriched Antimicrobial Peptide-2 Decreases During Male Puberty
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
bvac013.pdf
Size:
3.58 MB
Format:
Adobe Portable Document Format